Trial intelligence / Profile preview

BI 409306 in patients with cognitive impairment due to Alzheimer's disease

2013-005040-28Phase 2Completed

Sponsor
Boehringer Ingelheim
Start
Nov 2014
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing BI 409306 + donepezil with Placebo + donepezil (2 arms). Primary endpoint: Cognition (NTB total score). Started Nov 2014; status: completed.

02

Drugs

osoresnontrine
03

Conditions

Alzheimer's disease (AD)

Beyond the preview

Go deeper on 2013-005040-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-005040-28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call